Literature DB >> 32435363

Discovery of New 1,1'-Biphenyl-4-sulfonamides as Selective Subnanomolar Human Carbonic Anhydrase II Inhibitors.

Giuseppe La Regina1, Michela Puxeddu1, Marianna Nalli1, Daniela Vullo2, Paola Gratteri3, Claudiu Trandafir Supuran2, Alessio Nocentini2,3, Romano Silvestri1.   

Abstract

We report here the synthesis and human carbonic anhydrases (CA, EC 4.2.1.1) inhibitory properties of a series of 4'-substituted 1,1'-biphenyl-4-sulfonamides incorporating a 2″- or 3″-amino- or carboxyphenyl unit. Most compounds showed significant variations in their inhibition profiles against CA II and IX when compared to previously reported analogs 12-18 bearing a 4″-amino or a 4″-carboxy group. In particular, compounds 1-11 showed considerable improvement of the CA II inhibitory efficacy with K I values in the subnanomolar range (K Is spanning between 0.57 and 31.0 nM), a drop of activity against CA IX (K Is in the range 92.0 to 555.7 nM) and were as potent as 12-18 toward CA I (K Is in the range 5.9-217.7 nM). Docking and molecular dynamics were used to gain insights on the inhibition profiles. The reported inhibition data show that 1-11 have potential as novel agents to treat ocular pathologies, such as glaucoma, because of the potent and selective targeting of CA II, which is the isoform most implicated in this disease.
Copyright © 2019 American Chemical Society.

Entities:  

Year:  2019        PMID: 32435363      PMCID: PMC7236029          DOI: 10.1021/acsmedchemlett.9b00437

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  16 in total

Review 1.  Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?

Authors:  Vincenzo Alterio; Anna Di Fiore; Katia D'Ambrosio; Claudiu T Supuran; Giuseppina De Simone
Journal:  Chem Rev       Date:  2012-05-18       Impact factor: 60.622

2.  Prevention of acute mountain sickness by acetazolamide: as yet an unfinished story.

Authors:  Erik R Swenson; Luc J Teppema
Journal:  J Appl Physiol (1985)       Date:  2006-12-28

Review 3.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators.

Authors:  Claudiu T Supuran
Journal:  Nat Rev Drug Discov       Date:  2008-02       Impact factor: 84.694

4.  Carbonic anhydrases.

Authors:  Claudiu T Supuran
Journal:  Bioorg Med Chem       Date:  2013-03-15       Impact factor: 3.641

Review 5.  Interfering with pH regulation in tumours as a therapeutic strategy.

Authors:  Dario Neri; Claudiu T Supuran
Journal:  Nat Rev Drug Discov       Date:  2011-09-16       Impact factor: 84.694

Review 6.  Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery.

Authors:  Alessio Nocentini; Claudiu T Supuran
Journal:  Expert Opin Drug Discov       Date:  2019-08-22       Impact factor: 6.098

Review 7.  Carbonic anhydrases as targets for medicinal chemistry.

Authors:  Claudiu T Supuran; Andrea Scozzafava
Journal:  Bioorg Med Chem       Date:  2007-04-19       Impact factor: 3.641

Review 8.  The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents.

Authors:  Francesco Mincione; Andrea Scozzafava; Claudiu T Supuran
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 9.  Glaucoma and the applications of carbonic anhydrase inhibitors.

Authors:  Andrea Scozzafava; Claudiu T Supuran
Journal:  Subcell Biochem       Date:  2014

Review 10.  The pathophysiology and treatment of glaucoma: a review.

Authors:  Robert N Weinreb; Tin Aung; Felipe A Medeiros
Journal:  JAMA       Date:  2014-05-14       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.